Compare INTS & RAYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTS | RAYA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 3.6M |
| IPO Year | 2021 | 2021 |
| Metric | INTS | RAYA |
|---|---|---|
| Price | $3.62 | $3.12 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | 23.8K | ★ 40.0K |
| Earning Date | 05-07-2026 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.03 |
| 52 Week High | $8.06 | $10.14 |
| Indicator | INTS | RAYA |
|---|---|---|
| Relative Strength Index (RSI) | 21.57 | 46.84 |
| Support Level | $0.31 | $0.27 |
| Resistance Level | $8.06 | $4.27 |
| Average True Range (ATR) | 0.21 | 0.45 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 15.60 | 9.63 |
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Erayak Power Solution Group Inc is engaged in the manufacturing, research and development (R&D), and wholesale and retail of power solution products. The group focuses on manufacturing new energy storage and inverter devices. Its product portfolio includes sine wave and off-grid inverters, inverters and gasoline generators, battery and smart chargers, and custom-designed products. The products are used principally in agricultural and industrial vehicles, recreational vehicles (RVs), electrical appliances, and outdoor living products. The company generates the majority of its revenue from Inverters. The company generates revenue from five main markets, which are China, Poland, Mexico, the U.K., and Portugal. It derives maximum revenue from China.